Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

PD-161989: novel AMPA/GLYN receptor antagonist related to PNQX

Nov. 11, 1998

Chugai describes inhibitors of iNOS, nNOS

Nov. 11, 1998

Synthelabo presents in vitro, ex vivo and in vivo data on new MAO-B inhibitor

Nov. 11, 1998

LY-300164 protects against kainate-induced neurotoxicity in vitro in a stereoselective manner

Nov. 11, 1998

Nonpeptide CRF1 antagonist developed at Parke-Davis modulates brain NE levels

Nov. 11, 1998

Knoll develops potential new antipsychotic agent with advantages over available therapies

Nov. 10, 1998

LEF-553: a potent mu-opioid receptor agonist with peripheral analgesic effects

Nov. 10, 1998

NK1 antagonist L-732138 exhibits activity indicating efficacy in neuropathic pain

Nov. 10, 1998

Novel sodium channel blocker from Roche evaluated in vitro for neuroprotective efficacy

Nov. 10, 1998

Reversible mixed MAO-A/MAO-B inhibitor discovered at Synthelabo is presented this week

Nov. 10, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...